Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 7 institutions in 3 countries.
Marta Alonso-PeñaExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-0934-2202
Ricardo Espinosa-EscuderoExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
Heike M HermannsDivision of Hepatology, Würzburg University Hospital, Medical Clinic II, 97080 Würzburg, Germany.ORCID 0000-0002-6617-1668
Oscar BrizExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-6891-1554
Jose M HerranzCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.ORCID 0000-0002-6031-535X
Carmen Garcia-RuizCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.
Jose C Fernandez-ChecaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.ORCID 0000-0003-2278-7724
Javier JuamperezPediatric Hepatology and Liver Transplantation Unit, Vall d'Hebron University Hospital (HVH), Universitat Autónoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-8556-6374
Matias AvilaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.ORCID 0000-0001-6570-3557
Josepmaria ArgemiCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.
Ramon BatallerCenter for Liver Diseases, Pittsburgh Liver Research Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0000-0002-1119-7799
Javier CrespoGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain.ORCID 0000-0001-8248-0172
Maria J MonteExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-1844-7428
Andreas GeierDivision of Hepatology, Würzburg University Hospital, Medical Clinic II, 97080 Würzburg, Germany.
Elisa HerraezExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0001-9271-3320
Jose J G MarinExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.ORCID 0000-0003-1186-6849
Universidad de Salamanca · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESUniversitätsklinikum Würzburg · DEUniversity of Southern California · USMarqués de Valdecilla University Hospital · ESUniversitat Autònoma de Barcelona · ESUniversity of Pittsburgh Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Bile acid (BA) synthesis from cholesterol by hepatocytes is inhibited by inflammatory cytokines. Whether liver inflammation also affects BA side chain shortening and conjugation was investigated. In human liver cell lines (IHH, HepG2, and HepaRG), agonists of nuclear receptors including the farnesoid X receptor (FXR), liver X receptor (LXR), and peroxisome proliferator-activated receptors (PPARs) did not affect the expression of BA-related peroxisomal enzymes. In contrast, hepatocyte nuclear factor 4α (HNF4α) inhibition down-regulated acyl-CoA oxidase 2 (ACOX2).
Indexed as
Bile Acids and SaltsHepatitisCholesterolCytokinesHumansInflammationTandem Mass SpectrometryBile Acids and SaltsCholesterolCytokinesACOX2ASHBAATbile acidinflammationNAFLNASHoncostatin M
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation. · full record | OpenQuestion